Today the FDA approved neoadjuvant EV and perioperative duvalumab in muscle invasive bladder during #UromigosLive . This is based on a +ve EFS & OS signal This gives and addition option to 9 cycles of perioperive EVP already approved. @Annals_Oncology@myESMO@OncoAlert https://t.co/MPb7g5rLqP
Approval of Pluvicto® for metastatic hormone-sensitive #ProstateCancer. @sartor_oliver@EJHospital joins @AarmstrongDuke@DukeCancer to review #PSMAddition, covering FDA approval of lutetium-177 PSMA-617 added to a standard ADT plus ARPI doublet in metastatic hormone-sensitive prostate cancer. #WatchNow on UroToday > https://t.co/u6xdVP7CaV
Profesör olmak, otomatik olarak daha iyi hekim olmak değildir.
Bir onkoloji uzmanı, uzmanlık eğitimini tamamlamış bir onkologdur.
Profesörlük ise başka bir şeyi gösterir: akademik kariyer, bilimsel üretim, eğitim ve mentorluk.
Klinik yetkinlik; deneyim, güncel bilgi, karar kalitesi, ekip çalışması, iletişim ve hasta sonuçlarıyla şekillenir.
Akademik unvan da en doğru anlamını akademik görevin içinde bulur. Onu ticari, mesleki ya da sosyal alanlarda bir üstünlük işaretine dönüştürmek, hem unvana hem uzmanlığa haksızlıktır.
Akademik unvanı değerli kılarken uzmanlığı değersizleştirmemeliyiz.
Uzmanlık hasta başındaki yetkinliği, unvan ise akademideki sorumluluğu anlatır. İkisini karıştırdığımızda, ikisini de küçültürüz…
PCWG4 is published! #GU26 Thanks to @ThePCCTC and my co chairs Howard Scher and Mike Morrison and the 65 co-authors of these new trial guidelines! @DukeCancer@JCO_ASCO https://t.co/y6mlm2ScmW
🧾 New Cheat Sheet on Prostate Cancer Treatment by Stage
🔹 Low-risk: Active surveillance; avoid ADT
🔹 Intermediate-risk: Surgery or RT; ADT case-based
🔹 High-risk: Surgery/RT + long-term ADT
#EAUguidelines#ProstateCancer
Download Cheat Sheet here:
https://t.co/IvTGHuFWt6
8-year outcomes of enzalutamide vs a non-steroidal anti-androgen for metastatic, hormone-sensitive #ProstateCancer (ENZAMET; ANZUP 1304). Presented by Alison Zhang, MD, PhD @Sydney_Uni. #ASCO25 written coverage by @RKSayyid@USC > https://t.co/5UUNf83t4i @ASCO
👏 Olaparib improved PFS and OS across subgroups of BRCA1/2mut #prostatecancer patients in the PROFOUND phase III trial ➡️ https://t.co/9L8NkaOWWI #PARPi#PCSM@quimmateo
EV302- enfortumab vedotin and Pembrolizumab met its dual primary endpoints of OS and PFS with ‘clinically meaningful’ improvement versus chemotherapy in patients with previously untreated la/mUC. https://t.co/NRb4DhQR2C
I have tweeted more than 500 times about current information in oncology.
My tweet below was the most retweeted tweet in the scientific community. The topic of the tweet is the success of topical diclofenac in reducing HFS.
I hope the pharmaceutical industry gets the message.
What we need is easy-to-access inexpensive drugs that we can easily administer to every patient. Cancer is a serious disease, and everyone in cancer care should have the right to equitable access to the most effective treatment. Let's make an effort to decrease drug prices!!!
@OncoAlert
#EquitableCancerCare
Breaking news👉Abiraterone+Olaparib approved in the European Union for new mCRPC #prostatecancer irrespective of HRRm. https://t.co/6VZ48LM2Mt Next approval is expected to be of Enzalutamide+Talazoparib (TALAPRO-2 Ph3 trial)👇@oncoalert@urotoday@guconnectinfo @FDAOncology
Press release IM130: Atezo vs chemo vs atezo/chemo in 1st line UC. “IMVigor130 did not cross the statistical threshold for OS”. Atezo withdrawn for 1st line UC in USA. ctDNA rather than PD-L1 maybe a better way of selecting patients for atezo. IMVigor011👍 https://t.co/KAcah0VCtV